Scholar Rock Holding Corp
Scholar Rock Holding Corp is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab on November 1, 2026. There are 4 upcoming events on record.
Cash runway is approximately 18 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 1, 2026 | Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab | Trial Milestone | Phase 3 |
| December 17, 2026 | A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy Adults | Trial Milestone | Phase 1 |
| June 15, 2028 | Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD | Trial Milestone | Phase 2 |
| November 15, 2028 | A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy | Trial Milestone | Phase 2 |
Track SRRK alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open SRRK in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.